Table 4. Univariate and multivariate... | American Society of Hematology

Table 4.

Univariate and multivariate analysis of prognostic markers as predictors of overall survival

Prognostic variable	Univariate			Multivariate
Prognostic variable	HR	95% CI	P	HR	95% CI	P
R-ISS > 1	2.75	1.48-5.13	.001*	2.75	1.03-7.38	.044*
Ki67/CD138† ≥ 5%	2.48	1.53-4.03	<.001*	1.84	1.06-3.18	.030*
Prior lines of therapy >3	1.97	1.22-3.19	.012*	1.38	.751-2.56	.302
Marrow plasmacytosis >60%	1.89	1.24-2.88	.003*	1.26	.744-2.12	.394
High risk cytogenetics (R-ISS)	1.62	1.06-2.48	.025*	1.04	.625-1.73	.874
Bortezomib refractory	1.27	.78-2.04	.337
Double refractory	1.26	.83-1.91	.282
Age >65 y	1.03	.70-3.28	1.514
Lenalidomide refractory	0.94	.56-1.58	.815

Prognostic variable	Univariate			Multivariate
Prognostic variable	HR	95% CI	P	HR	95% CI	P
R-ISS > 1	2.75	1.48-5.13	.001*	2.75	1.03-7.38	.044*
Ki67/CD138† ≥ 5%	2.48	1.53-4.03	<.001*	1.84	1.06-3.18	.030*
Prior lines of therapy >3	1.97	1.22-3.19	.012*	1.38	.751-2.56	.302
Marrow plasmacytosis >60%	1.89	1.24-2.88	.003*	1.26	.744-2.12	.394
High risk cytogenetics (R-ISS)	1.62	1.06-2.48	.025*	1.04	.625-1.73	.874
Bortezomib refractory	1.27	.78-2.04	.337
Double refractory	1.26	.83-1.91	.282
Age >65 y	1.03	.70-3.28	1.514
Lenalidomide refractory	0.94	.56-1.58	.815

HR, hazard ratio.

Statistically significant.

Ki67/CD138: percentage of CD138⁺ cells that stain positively for Ki67 on immunohistochemistry.